SCHEMBL5544549

SCHEMBL5544549

O=[C]OCCc1cc2ccc(Cl)cc2o1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.38
CA9 Q16790 1/20 0.38
DRD2 P14416 2/20 0.33
DRD1 P21728 2/20 0.33
DRD3 P35462 2/20 0.33
MAOB P27338 2/20 0.33
MAOA P21397 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
APP P05067 1/20 0.32
CYP19A1 P11511 1/20 0.32
PSMB8 P28062 2/20 0.32
PSMB5 P28074 1/20 0.32
SLC6A4 P31645 1/20 0.32
MIF P14174 1/20 0.31
DRD5 P21918 1/20 0.31
PIK3CG P48736 1/20 0.31
LMNA P02545 1/20 0.31
CYP1A2 P05177 1/20 0.31
ADRA2A P08913 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5541624 0.89 DRD3 (0.36) CA12CA9DRD2DRD1DRD3
SCHEMBL5545173 0.88 MAOB (0.44) CA12CA9MAOBCYP19A1CYP1A2
SCHEMBL5541845 0.82 L3MBTL1 (0.36) CA12CA9HDAC6APPMIF
SCHEMBL5542090 0.78 MAOB (0.40) CA12CA9DRD2DRD1DRD3
SCHEMBL10674648 0.74 LOXL2 (0.42) CA12CA9DRD2DRD1DRD3
SCHEMBL5542277 0.73 CA12 (0.38) CA12CA9HDAC6APP
SCHEMBL5537327 0.72 ATM (0.32) PSMB8PSMB5
SCHEMBL5539271 0.72 PPARG (0.35)
SCHEMBL5545088 0.72 L3MBTL1 (0.34) HDAC6
SCHEMBL21355070 0.72 CA12 (0.44) CA12CA9DRD2DRD1DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 CA12 1998/4885CA9 3134/4885DRD2 542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.